AU2006276182B2 - Improved methods and compositions for increasing longevity and protein yield from a cell culture - Google Patents

Improved methods and compositions for increasing longevity and protein yield from a cell culture Download PDF

Info

Publication number
AU2006276182B2
AU2006276182B2 AU2006276182A AU2006276182A AU2006276182B2 AU 2006276182 B2 AU2006276182 B2 AU 2006276182B2 AU 2006276182 A AU2006276182 A AU 2006276182A AU 2006276182 A AU2006276182 A AU 2006276182A AU 2006276182 B2 AU2006276182 B2 AU 2006276182B2
Authority
AU
Australia
Prior art keywords
cells
bcl
cell
cell line
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006276182A
Other languages
English (en)
Other versions
AU2006276182A1 (en
Inventor
Chien Hsing Chang
David M. Goldenberg
Diane Nordstrom
Zhengxing Qu
Edward A. Rossi
Jeng-Dar Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of AU2006276182A1 publication Critical patent/AU2006276182A1/en
Application granted granted Critical
Publication of AU2006276182B2 publication Critical patent/AU2006276182B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2006276182A 2005-07-25 2006-07-14 Improved methods and compositions for increasing longevity and protein yield from a cell culture Active AU2006276182B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/187,863 US7531327B2 (en) 2004-07-23 2005-07-25 Methods and compositions for increasing longevity and protein yield from a cell culture
US11/187,863 2005-07-25
PCT/US2006/027820 WO2007015848A2 (en) 2005-07-25 2006-07-14 Improved methods and compositions for increasing longevity and protein yield from a cell culture

Publications (2)

Publication Number Publication Date
AU2006276182A1 AU2006276182A1 (en) 2007-02-08
AU2006276182B2 true AU2006276182B2 (en) 2012-02-16

Family

ID=37709058

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006276182A Active AU2006276182B2 (en) 2005-07-25 2006-07-14 Improved methods and compositions for increasing longevity and protein yield from a cell culture

Country Status (8)

Country Link
US (1) US7531327B2 (enExample)
EP (1) EP1910515B1 (enExample)
JP (2) JP5301990B2 (enExample)
KR (2) KR20130027579A (enExample)
CN (1) CN101273121B (enExample)
AU (1) AU2006276182B2 (enExample)
CA (1) CA2616799C (enExample)
WO (1) WO2007015848A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537930B2 (en) * 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
KR101794638B1 (ko) * 2008-06-10 2017-12-04 상가모 테라퓨틱스, 인코포레이티드 Ｂａｘ- 및 ｂａｋ-결함 세포주들의 제조 방법 및 조성물
SI2331678T1 (sl) * 2008-06-13 2015-12-31 Janssen Biotech, Inc. Postopki za dobivanje visoke gostote viabilnih celic v sesalski celični kulturi
DE102008051574A1 (de) * 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
SG173469A1 (en) 2009-02-20 2011-09-29 Ventria Bioscience Cell culture media containing combinations of proteins
CN101899471B (zh) * 2009-05-26 2014-06-11 中国医学科学院基础医学研究所 同时表达抗原特异性受体和外源基因的重组逆转录病毒载体、用其修饰的b-淋巴细胞及其用途
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
US20120028933A1 (en) 2010-07-28 2012-02-02 Baust John M Cell Culture Media Supplement and Method of Molecular Stress Control
JP5665065B2 (ja) 2011-04-28 2015-02-04 国立大学法人大阪大学 リソソーム病治療用医薬組成物
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EP2970915B1 (en) * 2013-03-15 2019-08-14 Maxcyte, Inc. Methods and compositions for generating stable transfected cells
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
ES2833471T3 (es) * 2013-10-11 2021-06-15 Regeneron Pharma Cultivo celular metabólicamente optimizado
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
AU2015328370B2 (en) 2014-10-07 2021-08-05 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
KR20170135966A (ko) 2015-04-13 2017-12-08 맥스시티 인코포레이티드 게놈 dna를 변형시키기 위한 방법 및 조성물
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
JP6835815B2 (ja) * 2015-07-17 2021-02-24 アレス トレーディング ソシエテ アノニム 組み換えタンパク質の産生プロファイルを修飾する方法
TWI784063B (zh) * 2017-12-27 2022-11-21 財團法人生物技術開發中心 具有增進蛋白質表現功效的宿主細胞及其用途
CN120174006A (zh) * 2018-07-13 2025-06-20 隆萨有限公司 用于通过降低内源性蛋白质的水平来改善生物产物的生产的方法
CN111349615B (zh) * 2018-12-24 2024-08-13 上海细胞治疗集团股份有限公司 制备过表达外源基因的细胞的方法
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
WO2023096380A1 (ko) * 2021-11-26 2023-06-01 한양대학교 산학협력단 유전자 과발현을 이용해 조건부 성숙이 가능한 적혈구 전구세포주 확립

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219871A1 (en) * 2002-03-28 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Host cells having improved cell survival properties and methods to generate such cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0471484A (ja) * 1990-07-11 1992-03-06 Teijin Ltd 低凝集性細胞及びその培養方法
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU7614600A (en) * 1999-09-27 2001-04-30 Genentech Inc. Methods for making recombinant proteins using apoptosis inhibitors
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
US7604989B2 (en) 2001-07-10 2009-10-20 Johns Hopkins University Inhibition of apoptosis process and improvement of cell performance
WO2003040374A1 (en) 2001-11-02 2003-05-15 Centocor, Inc. METHODS AND COMPOSITIONS FOR ENHANCED PROTEIN EXPRESSION AND/OR GROWTH OF CULTURED CELLS USING CO-TRANSCRIPTION OF A Bcl2 ENCODING NUCLEIC ACID
US6964199B2 (en) 2001-11-02 2005-11-15 Cantocor, Inc. Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
EP1490481A4 (en) * 2001-12-14 2005-12-07 Centocor Inc CLONAL CELL LINES OF MYELOMES FOR PRODUCING PROTEINS IN A CHEMICALLY DEFINED ENVIRONMENT
EP1348758A1 (en) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Host cells having improved cell survival properties and methods to generate such cells
EP1563073A4 (en) * 2002-06-26 2007-09-19 Biogen Idec Inc PROTEIN PRODUCTION METHODS AND MODIFIED CELLS FOR USE IN SUCH METHODS
CA2542121A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Genomically modified cell neutralized to serum-free system
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
CN1287862C (zh) * 2004-09-29 2006-12-06 中国人民解放军第四军医大学 MG7－Ag模拟表位构建胃癌特异性多表位基因疫苗的方法
US20070092947A1 (en) 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219871A1 (en) * 2002-03-28 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Host cells having improved cell survival properties and methods to generate such cells

Also Published As

Publication number Publication date
EP1910515B1 (en) 2019-02-27
KR101518062B1 (ko) 2015-05-28
AU2006276182A1 (en) 2007-02-08
US20060110793A1 (en) 2006-05-25
WO2007015848A3 (en) 2007-10-04
KR20080073282A (ko) 2008-08-08
CN101273121B (zh) 2012-07-04
WO2007015848A9 (en) 2007-04-05
WO2007015848B1 (en) 2007-11-15
KR20130027579A (ko) 2013-03-15
JP2013172722A (ja) 2013-09-05
CA2616799C (en) 2015-11-24
WO2007015848A2 (en) 2007-02-08
JP2009502167A (ja) 2009-01-29
EP1910515A2 (en) 2008-04-16
CN101273121A (zh) 2008-09-24
US7531327B2 (en) 2009-05-12
EP1910515A4 (en) 2009-03-11
JP5301990B2 (ja) 2013-09-25
CA2616799A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
AU2006276182B2 (en) Improved methods and compositions for increasing longevity and protein yield from a cell culture
US7785880B2 (en) Mammalian cell lines for increasing longevity and protein yield from cell culture
US7608425B2 (en) Methods for protein expression in mammalian cells in serum-free medium
EP2441831B9 (en) Process for production of protein
JP2012254084A (ja) 細胞培養物の寿命および由来するタンパク質の収率を増加させるための方法および組成物
EP2653540B9 (en) Protein production method
US20070092947A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
AU2005333513B2 (en) Methods and compositions for increasing longevity and protein yield from a cell culture

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ NORDSTROM, DIANE; QU, ZHENGXING; CHANG, CHIEN HSING; GOLDENBERG, DAVID M.; YANG, JENG-DAR AND ROSSI, EDWARD A.

FGA Letters patent sealed or granted (standard patent)